;PMID: 3539825
;source_file_2861.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)sentence:[e:44..95] = [t:44..95]
;2)section:[e:99..188] = [t:99..188]
;3)sentence:[e:192..339] = [t:192..339]
;4)sentence:[e:341..471] = [t:341..471]
;5)sentence:[e:472..679] = [t:472..679]
;6)sentence:[e:680..814] = [t:680..814]
;7)sentence:[e:815..1062] = [t:815..1062]
;8)sentence:[e:1063..1177] = [t:1063..1177]
;9)sentence:[e:1178..1323] = [t:1178..1323]
;10)section:[e:1327..1371] = [t:1327..1371]

;section 0 Span:0..38
;Int J Cancer.  1987 Jan 15;39(1):73-6.
(SEC
  (FRAG (NNP:[0..3] Int) (NNP:[4..5] J) (NNP:[6..12] Cancer) (.:[12..13] .)
        (CD:[15..19] 1987) (CC:[20..23] Jan) (CD:[24..29] 15;39)
        (-LRB-:[29..30] -LRB-) (CD:[30..31] 1) (-RRB-:[31..32] -RRB-)
        (CD:[32..35] :73) (HYPH:[35..36] -) (CD:[36..38] 6.)))

;sentence 1 Span:44..95
;Shedding of GD2 ganglioside by human neuroblastoma.
;[81..94]:malignancy-type:"neuroblastoma"
(SENT
  (NP
    (NP (NN:[44..52] Shedding))
    (PP (IN:[53..55] of)
      (NP (NN:[56..59] GD2) (NN:[60..71] ganglioside)))
    (PP (IN:[72..74] by)
      (NP (JJ:[75..80] human) (NN:[81..94] neuroblastoma)))
    (.:[94..95] .)))

;section 2 Span:99..188
;Ladisch S, Wu ZL, Feig S, Ulsh L, Schwartz E, Floutsis G, Wiley F, Lenarsky
;C,  Seeger R.
(SEC
  (FRAG (NNP:[99..106] Ladisch) (NNP:[107..108] S) (,:[108..109] ,)
        (NNP:[110..112] Wu) (NNP:[113..115] ZL) (,:[115..116] ,)
        (NNP:[117..121] Feig) (NNP:[122..123] S) (,:[123..124] ,)
        (NNP:[125..129] Ulsh) (NNP:[130..132] L,) (NNP:[133..141] Schwartz)
        (NNP:[142..143] E) (,:[143..144] ,) (NNP:[145..153] Floutsis)
        (NNP:[154..155] G) (,:[155..156] ,) (NNP:[157..162] Wiley)
        (NNP:[163..164] F) (,:[164..165] ,) (NNP:[166..174] Lenarsky)
        (NNP:[175..176] C) (,:[176..177] ,) (NNP:[179..185] Seeger)
        (NNP:[186..188] R.)))

;sentence 3 Span:192..339
;Substantial concentrations of the cell-surface glycosphingolipid, the 
;disialoganglioside GD2, are uniformly present in human neuroblastoma tumors.
;[318..331]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[192..203] Substantial) (NNS:[204..218] concentrations))
      (PP (IN:[219..221] of)
        (NP
          (NP (DT:[222..225] the)
            (NML (NN:[226..230] cell) (HYPH:[230..231] -)
                 (NN:[231..238] surface))
            (NN:[239..256] glycosphingolipid))
          (,:[256..257] ,)
          (NP (DT:[258..261] the) (NN:[263..281] disialoganglioside)
              (NN:[282..285] GD2)))))
    (,:[285..286] ,)
    (VP (VBP:[287..290] are)
      (ADJP-PRD (RB:[291..300] uniformly) (JJ:[301..308] present)
        (PP-LOC (IN:[309..311] in)
          (NP (JJ:[312..317] human) (NN:[318..331] neuroblastoma)
              (NNS:[332..338] tumors)))))
    (.:[338..339] .)))

;sentence 4 Span:341..471
;This ganglioside can also be detected in the plasma of patients with 
;neuroblastoma by direct thin-layer chromatographic analysis.
;[411..424]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ-1 (DT:[341..345] This) (NN:[346..357] ganglioside))
    (VP (MD:[358..361] can)
      (ADVP (RB:[362..366] also))
      (VP (VB:[367..369] be)
        (VP (VBN:[370..378] detected)
          (NP-1 (-NONE-:[378..378] *))
          (PP-LOC (IN:[379..381] in)
            (NP
              (NP (DT:[382..385] the) (NN:[386..392] plasma))
              (PP (IN:[393..395] of)
                (NP
                  (NP (NNS:[396..404] patients))
                  (PP (IN:[405..409] with)
                    (NP (NN:[411..424] neuroblastoma)))))))
          (PP-MNR (IN:[425..427] by)
            (NP (JJ:[428..434] direct)
              (NML (JJ:[435..439] thin) (HYPH:[439..440] -)
                   (NN:[440..445] layer))
              (JJ:[446..461] chromatographic) (NN:[462..470] analysis))))))
    (.:[470..471] .)))

;sentence 5 Span:472..679
;Among 32  neuroblastoma patients in all clinical stages studied prior to the
;initiation of  treatment, 27 (84%) showed measurably elevated plasma
;concentrations of GD2  (greater than or equal to 50 pmol/ml).
;[482..495]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (PP (IN:[472..477] Among)
      (NP
        (NP (CD:[478..480] 32) (NN:[482..495] neuroblastoma)
            (NNS:[496..504] patients))
        (PP (IN:[505..507] in)
          (NP
            (NP (DT:[508..511] all) (JJ:[512..520] clinical)
                (NNS:[521..527] stages))
            (VP (VBN:[528..535] studied)
              (NP (-NONE-:[535..535] *))
              (ADJP-TMP (JJ:[536..541] prior)
                (PP (TO:[542..544] to)
                  (NP
                    (NP (DT:[545..548] the) (NN:[549..559] initiation))
                    (PP (IN:[560..562] of)
                      (NP (NN:[564..573] treatment)))))))))))
    (,:[573..574] ,)
    (NP-SBJ (CD:[575..577] 27)
      (PRN (-LRB-:[578..579] -LRB-)
        (NP (CD:[579..581] 84) (NN:[581..582] %))
        (-RRB-:[582..583] -RRB-)))
    (VP (VBD:[584..590] showed)
      (NP
        (NP
          (ADJP (RB:[591..601] measurably) (VBN:[602..610] elevated))
          (NN:[611..617] plasma) (NNS:[618..632] concentrations))
        (PP (IN:[633..635] of)
          (NP (NN:[636..639] GD2))))
      (PRN (-LRB-:[641..642] -LRB-)
        (NP
          (NP
            (QP (JJR:[642..649] greater) (IN:[650..654] than) (CC:[655..657] or)
                (JJ:[658..663] equal) (TO:[664..666] to) (CD:[667..669] 50))
            (NN:[670..674] pmol))
          (PP (SYM:[674..675] /)
            (NP (NN:[675..677] ml))))
        (-RRB-:[677..678] -RRB-)))
    (.:[678..679] .)))

;sentence 6 Span:680..814
;The mean level (545 +/- 108 pmol/ml) was  more than 50 times the normal
;plasma GD2 concentration of less than or equal to  10 pmol/ml.
(SENT
  (S
    (NP-SBJ (DT:[680..683] The) (JJ:[684..688] mean) (NN:[689..694] level)
      (PRN (-LRB-:[695..696] -LRB-)
        (NP
          (NP
            (QP (CD:[696..699] 545) (SYM:[700..703] +/-) (CD:[704..707] 108))
            (NN:[708..712] pmol))
          (PP (SYM:[712..713] /)
            (NP (NN:[713..715] ml))))
        (-RRB-:[715..716] -RRB-)))
    (VP (VBD:[717..720] was)
      (ADJP-PRD
        (ADJP (JJR:[722..726] more))
        (PP (IN:[727..731] than)
          (NP
            (NP
              (QP (CD:[732..734] 50) (NNS:[735..740] times))
              (DT:[741..744] the) (JJ:[745..751] normal) (NN:[752..758] plasma)
               (NN:[759..762] GD2) (NN:[763..776] concentration))
            (PP (IN:[777..779] of)
              (NP
                (NP
                  (QP (JJR:[780..784] less) (IN:[785..789] than)
                      (CC:[790..792] or) (JJ:[793..798] equal)
                      (TO:[799..801] to) (CD:[803..805] 10))
                  (NN:[806..810] pmol))
                (PP (SYM:[810..811] /)
                  (NP (NN:[811..813] ml)))))))))
    (.:[813..814] .)))

;sentence 7 Span:815..1062
;Circulating GD2 was not detected in the plasma of patients with the  related,
;more differentiated tumors, ganglioneuroblastoma and ganglioneuroma, 
;indicating an association of the shedding of this ganglioside with the 
;undifferentiated phenotype.
;[921..941]:malignancy-type:"ganglioneuroblastoma"
;[946..960]:malignancy-type:"ganglioneuroma"
(SENT
  (S
    (NP-SBJ-1 (VBG:[815..826] Circulating) (NN:[827..830] GD2))
    (VP (VBD:[831..834] was) (RB:[835..838] not)
      (VP (VBN:[839..847] detected)
        (NP-1 (-NONE-:[847..847] *))
        (PP-LOC (IN:[848..850] in)
          (NP
            (NP (DT:[851..854] the) (NN:[855..861] plasma))
            (PP (IN:[862..864] of)
              (NP
                (NP (NNS:[865..873] patients))
                (PP (IN:[874..878] with)
                  (NP
                    (NP (DT:[879..882] the) (VBN:[884..891] related)
                        (,:[891..892] ,)
                      (ADJP (RBR:[893..897] more)
                            (VBN:[898..912] differentiated))
                      (NNS:[913..919] tumors))
                    (,:[919..920] ,)
                    (NP (NN:[921..941] ganglioneuroblastoma) (CC:[942..945] and)
                        (NN:[946..960] ganglioneuroma))))))))
        (,:[960..961] ,)
        (S-ADV
          (NP-SBJ (-NONE-:[961..961] *))
          (VP (VBG:[963..973] indicating)
            (NP
              (NP (DT:[974..976] an) (NN:[977..988] association))
              (PP (IN:[989..991] of)
                (NP
                  (NP (DT:[992..995] the) (NN:[996..1004] shedding))
                  (PP (IN:[1005..1007] of)
                    (NP (DT:[1008..1012] this) (NN:[1013..1024] ganglioside)))))
              (PP (IN:[1025..1029] with)
                (NP (DT:[1030..1033] the) (JJ:[1035..1051] undifferentiated)
                    (NN:[1052..1061] phenotype))))))))
    (.:[1061..1062] .)))

;sentence 8 Span:1063..1177
;Circulating GD2 diminished in patients in response  to therapy, and
;reappeared in patients whose disease recurred.
(SENT
  (S
    (NP-SBJ (VBG:[1063..1074] Circulating) (NN:[1075..1078] GD2))
    (VP
      (VP (VBD:[1079..1089] diminished)
        (PP-LOC (IN:[1090..1092] in)
          (NP (NNS:[1093..1101] patients)))
        (PP (IN:[1102..1104] in)
          (NP
            (NP (NN:[1105..1113] response))
            (PP (TO:[1115..1117] to)
              (NP (NN:[1118..1125] therapy))))))
      (,:[1125..1126] ,) (CC:[1127..1130] and)
      (VP (VBD:[1131..1141] reappeared)
        (PP-LOC (IN:[1142..1144] in)
          (NP
            (NP (NNS:[1145..1153] patients))
            (SBAR
              (WHNP-1 (WP$:[1154..1159] whose) (NN:[1160..1167] disease))
              (S
                (NP-SBJ-1 (-NONE-:[1167..1167] *T*))
                (VP (VBD:[1168..1176] recurred))))))))
    (.:[1176..1177] .)))

;sentence 9 Span:1178..1323
;The results  suggest that the sequential determination of circulating GD2
;will be of value in  monitoring individual patients with neuroblastoma.
;[1309..1322]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ (DT:[1178..1181] The) (NNS:[1182..1189] results))
    (VP (VBP:[1191..1198] suggest)
      (SBAR (IN:[1199..1203] that)
        (S
          (NP-SBJ
            (NP (DT:[1204..1207] the) (JJ:[1208..1218] sequential)
                (NN:[1219..1232] determination))
            (PP (IN:[1233..1235] of)
              (NP (VBG:[1236..1247] circulating) (NN:[1248..1251] GD2))))
          (VP (MD:[1252..1256] will)
            (VP (VB:[1257..1259] be)
              (PP-PRD (IN:[1260..1262] of)
                (NP (NN:[1263..1268] value)))
              (PP (IN:[1269..1271] in)
                (S-NOM
                  (NP-SBJ (-NONE-:[1271..1271] *))
                  (VP (VBG:[1273..1283] monitoring)
                    (NP
                      (NP (JJ:[1284..1294] individual)
                          (NNS:[1295..1303] patients))
                      (PP (IN:[1304..1308] with)
                        (NP (NN:[1309..1322] neuroblastoma))))))))))))
    (.:[1322..1323] .)))

;section 10 Span:1327..1371
;PMID: 3539825 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1327..1331] PMID) (::[1331..1332] :) (CD:[1333..1340] 3539825)
        (NN:[1341..1342] -LSB-) (NNP:[1342..1348] PubMed) (::[1349..1350] -)
        (NN:[1351..1358] indexed) (IN:[1359..1362] for)
        (NNP:[1363..1371] MEDLINE-RSB-)))
